Cry for Low Cost Drugs to Propel Lipodystrophy Syndrome Market

San Francisco, California, July 19, 2017: A new TMR Research report, titled “HIV Associated Lipodystrophy Syndrome Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 – 2025” studies in detail the global market for a syndrome called HIV associated lipodystrophy. This syndrome is commonly found in patients suffering from human immune-deficiency virus (HIV) who are administered with antiretroviral drugs for treating the HIV infection. The report provides a comprehensive overview of the current and future scenario of the international HIV associated lipodystrophy syndrome market.

Human Immuno-deficiency Virus (HIV) is a disease with a complicated mix of symptoms that severely affect the human immune system. Lipodystrophy is a condition where a HIV infected patient suffers an ample amount of subcutaneous fat loss in their body. The lipodystrophy syndrome exhibits very complex morphological signs that hinder the process of understanding the anatomy of the disease and thus, researchers face significant challenges in finding cure for the syndrome. Patients diagnosed with advanced stage of HIV disease are more susceptible to develop HIV associated lipodystrophy syndrome.

In terms of treatment, currently there is a scarcity of effective medications for the different morphological changes that occur due to HIV associated lipodystrophy. Adequate exercise routine, which include different cardiovascular and strengthening exercises is most commonly recommended. Along with the workout, a planned nutrition diet is also recommended. Such dietary modification therapy has proven effective but its high cost hinders the large scale adoption. The treatment demands constant supply of energy packed foods for patients in order to maintain a standard level of sugar/fats in the body.

The report suggests that majority of HIV affected population exists in the underdeveloped or poor countries particularly in the Saharan-Africa region. Affording high cost treatment thus becomes very hard for people living in these regions. Healthcare companies worldwide are now considering to give out low-cost drugs in these areas. Also, the report suggests the entry of Asia healthcare companies is going to spark more decline in the cost of drugs for treating the HIV associated lipodystrophy syndrome. The market is driven by this growing competition and increasing spread of HIV infected population.

Geographically, North America and Europe are expected to contribute significantly in terms market share. Primary reason for this is the high affordability of patients in these regions. Asia Pacific region is also expected to contribute substantially to the global HIV associated lipodystrophy syndrome market. The rapidly increasing population and improving infrastructure for healthcare make Asia Pacific region a huge potential market. On the flip side, scarcity of affordable drugs is impeding the market to reach its highest potential.

Some of the prominent healthcare corporates in the global HIV associated lipodystrophy syndrome market include Gilead Sciences Inc., Abbott Laboratories, Amylin Pharmaceuticals Inc., Theratechnologies Inc., and Amgen Inc. The report mentions profiles of the aforementioned companies along with several others to provide insights into the market’s competitive landscape. These companies are spending large amount of fund into the research and development of new and effective cure to stay relevant in the global HIV associated lipodystrophy syndrome market.